← Back to Clinical Trials
Recruiting NCT07663994

NCT07663994 Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control Cohort

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07663994
Status Recruiting
Phase
Sponsor Institut Claudius Regaud
Condition Healthy Volunteers (Cancer)
Study Type INTERVENTIONAL
Enrollment 68 participants
Start Date 2026-06-30
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL).

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68 participants in total. It began in 2026-06-30 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pilot, prospective, mono-center study conducted in a population of healthy participants (free of cancer) for the analytical validation of circulating DNA analysis methods. The participants are employees of the institution. Their recruitement is carried out via internal posting (intranet and bulletin boards). The study participation will be strictly voluntary and without consequences on the professional situation of the participants.

Eligibility Criteria

Inclusion Criteria: * 1 Adult volunteer (≥ 18 y.o.) * 2 Participant free of cancer * 3 Participant belonging to the personnel of Oncopole Claudius Regaud (IUCT-O) institution * 4 Participant affiliated to a Social Health Insurance in France * 5 Participant who received clear and understandable information about the research * 6 Participant who signed an informed consent form before inclusion into the study and before any study specific procedure * 7 Participant who accepts a blood draw in the context of the research * 8 Participant who agrees to be contacted in the event of an incidental finding of a potential genetic abnormality Exclusion Criteria: * 1 Participant presenting with an associated pathology potentially preventing the adequate conduct of the study procedure * 2 Participant presenting with a contra-indication to blood draw * 3 Participant who reports to the investigator team * 4 Participant who has forfeited his/her freedom bu administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)

Contact & Investigator

Central Contact

Laura KELLER, PhD

✉ keller.laura@iuct-oncopole.fr

📞 0033 5 31 15 52 14

Frequently Asked Questions

Who can join the NCT07663994 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Volunteers (Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07663994 currently recruiting?

Yes, NCT07663994 is actively recruiting participants. Contact the research team at keller.laura@iuct-oncopole.fr for enrollment information.

Where is the NCT07663994 trial being conducted?

This trial is being conducted at Toulouse, France.

Who is sponsoring the NCT07663994 clinical trial?

NCT07663994 is sponsored by Institut Claudius Regaud. The trial plans to enroll 68 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology